Showing 1,523 results

Filters Content type: News, Editors' picks Topic: Pharmaceutical industry

News and information on drug companies, the cost of therapies, patent protections and generic medicines.

Pharmaceutical industry

Untangling the Trump administration's lawsuit over an HIV prevention drug

Editor's pick
Science
11 November 2019
Pharmaceutical industry

U.S. sues drugmaker Gilead over patents on HIV prevention treatment

Editor's pick
San Francisco Chronicle
8 November 2019
Bad science & bogus treatments

Misleading Ads About PrEP Are Threatening Progress to End the HIV Epidemic. They Must Be Removed.

Editor's pick
TheBodyPro
7 November 2019
PrEP policies & guidelines

United States Files Patent Infringement Lawsuit Against Gilead Related to Truvada® and Descovy® for Pre-exposure Prophylaxis of HIV

Editor's pick
U.S. Department of Health & Human Services
7 November 2019
PrEP policies & guidelines

Much Ado About Descovy

Editor's pick
TheBody
16 October 2019
Pharmaceutical industry

Gilead's Descovy nabs PrEP nod. Next step: Convert Truvada patients before generics hit

Editor's pick
FiercePharma
4 October 2019
Pharmaceutical industry

AIDS United Signals Change Following Gilead Controversy

Editor's pick
My Fabulous Disease
30 September 2019
New & experimental HIV treatments

European Commission Approves Trogarzo

Editor's pick
Global Newswire
27 September 2019
Activism & civil society

HIV Organizations and Workers Should Routinely Disclose Ties to Pharma Industry

Editor's pick
TheBodyPro
27 September 2019
Side effects

Unsure whether I'll join Gilead lawsuit

Editor's pick
Bay Area Reporter
27 September 2019
Pharmaceutical industry

Gilead Duped Me into Being Their Mouthpiece. Here’s How.

Editor's pick
My Fabulous Disease
25 September 2019
Pharmaceutical industry

Advocates say Gilead broke antitrust laws

Editor's pick
Bay Area Reporter
19 September 2019
Pharmaceutical industry

Gilead's Truvada keeps up PrEP TV push, lands at No. 2 in August ad spending

Editor's pick
FiercePharma
17 September 2019
PrEP policies & guidelines

A New Oral PrEP Strategy Is On the Horizon, But Who’s Going to Get It?

Editor's pick
AVAC
29 August 2019
Side effects

Those Truvada Lawsuit Ads You See Everywhere May Hinder Public Health Efforts

Editor's pick
TheBody
28 August 2019
Finance & funding

AIDS group official resigns over group's acceptance of drug company funds

Editor's pick
Washington Blade
27 August 2019
Pharmaceutical industry

Gilead to challenge US patents on HIV drug Truvada

Editor's pick
Financial Times
22 August 2019
Access to healthcare

New Drug For Drug-Resistant TB Has Great Promise. But How Much Will It Cost?

Editor's pick
NPR
17 August 2019
Drug-resistant TB

Promising new tuberculosis drug approved, but will it be affordable?

Editor's pick
Médecins Sans Frontières (MSF)
16 August 2019
TB treatment

Statement from Treatment Action Group on U.S. FDA Approval of Pretomanid

Editor's pick
Treatment Action Group
15 August 2019
Injectable & long-acting HIV treatment

DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

Editor's pick
DURECT press release
6 August 2019
The search for a cure

Industry $$ for HIV Cure Sparse Due to Unanswered Questions

Editor's pick
MedPage Today
3 August 2019
Pharmaceutical industry

Can new Dovato data jump-start uptake of 2-drug HIV regimen? ViiV hopes so

Editor's pick
FiercePharma
24 July 2019
PrEP

Market for HIV Prevention Drugs May More Than Double, Citi Says

Editor's pick
Bloomberg
21 July 2019